IIM Clinical Trials

22 recruitingLast updated: May 21, 2026

There are 22 actively recruiting iim clinical trials across 14 countries. Studies span Early Phase 1, Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4. Top locations include Philadelphia, Pennsylvania, United States, Wuhan, Hubei, China, Durham, North Carolina, United States. Updated daily from ClinicalTrials.gov.


IIM Trials at a Glance

22 actively recruiting trials for iim are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Early Phase 1 with 6 trials, with the heaviest enrollment activity in Philadelphia, Wuhan, and Durham. Lead sponsors running iim studies include CytoCares Inc, Nanjing Bioheng Biotech Co., Ltd., and Cabaletta Bio.

About IIM Clinical Trials

Looking for clinical trials for IIM? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IIM trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IIM clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory MyopathyAnti-synthetase Syndrome+5 more
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Not Applicable

MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery

PeriodontitisPeriimplantitis
University Hospital Muenster84 enrolled1 locationNCT07414498
Recruiting

Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies (IIMs)
Peking University People's Hospital10 enrolled1 locationNCT07564271
Recruiting
Phase 2Phase 3

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS
Restem, LLC.40 enrolled2 locationsNCT07160205
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies
CytoCares Inc6 enrolled1 locationNCT07193810
Recruiting
Not Applicable

Microbiological Evaluation of the Effectiveness of Different Surface Decontamination Protocols for Dental Implants

Dental Implant FailurePeriimplant DiseasesDental Implant Complications
University of Zagreb90 enrolled1 locationNCT07529444
Recruiting
Early Phase 1

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

SLESystemic SclerosisNMOSD+4 more
Nanjing Bioheng Biotech Co., Ltd.18 enrolled1 locationNCT06775912
Recruiting
Phase 1

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.38 enrolled5 locationsNCT07331272
Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

DermatomyositisInflammatory MyopathyInclusion Body Myositis+9 more
Myositis International Health & Research Collaborative Alliance Foundation700 enrolled1 locationNCT07374107
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

ANCA Associated Vasculitis (AAV)SLE - Systemic Lupus ErythematosusSSc-Systemic Sclerosis+3 more
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07315087
Recruiting
Early Phase 1

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy (IIM)
Daishi Tian12 enrolled1 locationNCT07086404
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Not Applicable

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Systemic Lupus ErythematosusSjogren's SyndromeSystemic Sclerosis (SSc)+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University15 enrolled1 locationNCT06614270
Recruiting
Early Phase 1

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

SLEANCA-associated VasculitisIIM+5 more
Nanjing Bioheng Biotech Co., Ltd.84 enrolled1 locationNCT07203404
Recruiting
Early Phase 1

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Immune Thrombocytopenia (ITP)Idiopathic Inflammatory Myopathies(IIM)
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT07174843
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960